(R)-methyl 2-(cyclohexylamino)propanoate | 91016-70-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-methyl 2-(cyclohexylamino)propanoate
• 英文别名: 2--propionsaeuremethylester；N-Cyclohexyl-DL-alanin-methylester；Methyl 2-(cyclohexylamino)propanoate
• CAS: 91016-70-5
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: CYYHAJIYMLADAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二氯-5 硝基嘧啶 、 (R)-methyl 2-(cyclohexylamino)propanoate 以53.12 %的产率得到methyl 2-[(2-chloro-5-nitropyrimidin-4-yl)-cyclohexylamino]propanoate
  参考文献：
  名称：

  US2024316054A1

  摘要：

  公开号：
• 作为产物：
  描述：

  Dl-丙氨酸甲酯 在 AMINOHIPPURATE SODIUM 作用下， 生成 (R)-methyl 2-(cyclohexylamino)propanoate
  参考文献：
  名称：

  US2024316054A1

  摘要：

  公开号：

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN
  申请人：Shiseido Company, Limited

  公开号：EP1884230A1

  公开（公告）日：2008-02-06

  The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin -inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and to further provide an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor agent, pore-shrinking agent, or rough skin preventing/amaliorating agent comprises one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof. The external composition for skin comprises the one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent.

  该发明提供了一种具有角化不全抑制、收缩毛孔或防止/改善粗糙皮肤功能的抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂，不会引起感觉刺激等安全问题，非常安全，并进一步提供了一种外用皮肤组合物，其中添加了具有上述功能的化合物。角化不全抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂包括从α-氨基酸衍生物和其盐组成的群中选择的一种、两种或更多化合物。外用皮肤组合物包括从α-氨基酸衍生物和其盐组成的群中选择的一种、两种或更多化合物，作为上述角化不全抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂。
• Synthesis of Several Disubstituted Sydnones
  作者：Devindra Dhawan、Lemont B. Kier

  DOI：10.1002/jps.2600530116

  日期：1964.1

  A number of new 3,4-dialkylsydnones have been prepared to compare their pharmacological properties with those of a series of 3-alkylsydnones. Both series were similar in their central convulsive activity. The CD 50 and partition coefficient values of both series were compared. The CD 50 values for the 3,4-dialkylsydnones were significantly lower than for the 3-alkylsydnones. In addition, the CD 50

  已经制备了许多新的3，4-二烷基sydnones以将它们的药理特性与一系列3-烷基sydnones的药理特性进行比较。两个系列的中央抽搐活动相似。比较两个系列的CD 50和分配系数值。3，4-二烷基sydnones的CD 50值明显低于3-烷基sydnones的CD 50值。另外，3，4-二烷基sydnones的CD 50值彼此接近，并且与分配系数无关。
• Peptidylaminodiols
  申请人：ABBOTT LABORATORIES

  公开号：EP0229667A2

  公开（公告）日：1987-07-22

  A renin inhibiting compound of the formula: wherein A is a substituent; W is C=O or CHOH; U is CH₂ or NR₂, provided that when W is CHOH then U is CH₂; R₁ is loweralkyl, cycloalkylmethyl, benzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)methyl, α, α -dimethylbenzyl, 1-benzyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino; R₂ is hydrogen or loweralkyl; R₃ is loweralkyl, [(alkoxy)alkoxy]alkyl, (thioalkoxy)alkyl, lowerakenyl, benzyl or heterocyclic ring substituted methyl; R₄ is loweralkyl, cycloalkylmethyl or benzyl; R₅ is vinyl, formyl, hydroxymethyl or hydrogen; R₇ is hydrogen or loweralkyl; R₈ and R₉ are independently selected from OH and NH₂; and R₆ is hydrogen, loweralkyl, vinyl or arylalkyl; provided that when R₅ and R₇ are both hydrogen and R₈ and R₉ are OH, the carbon bearing R₅ is of the "R" configuration and the carbon bearing R₆ is of the "S" configuration; or pharmaceutically acceptable salts or esters thereof. Also disclosed are renin inhibiting compositions, a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.

  式中的肾素抑制化合物： 其中 A 是取代基；W 是 C=O 或 CHOH；U 是 CH₂ 或 NR₂，条件是当 W 是 CHOH 时，U 是 CH₂；R₁ 是低级烷基、环烷基甲基、苄基、4-甲氧基苄基、卤代苄基、（1-萘基）甲基、（2-萘基）甲基、（4-咪唑酰）甲基、α、α-二甲基苄基、1-苄氧基乙基、苯乙基、苯氧基、噻吩氧基或苯胺基；R₂ 是氢或低级烷基；R₃ 是低级烷基、[(烷氧基)烷氧基]烷基、(硫代烷氧基)烷基、低级被烯基、苄基或杂环取代的甲基；R₄ 是低级烷基、环烷基甲基或苄基； R₅ 是乙烯基、甲酰基、羟甲基或氢； R₇ 是氢或低级烷基； R₈ 和 R𠢙 独立选自 OH 和 NH₂；以及 R₆ 是氢、低级烷基、乙烯基或芳基烷基；当 R₅ 和 R₇ 均为氢且 R₈ 和 R𠢙 均为 OH 时，含 R₅ 的碳为 "R "构型，含 R₆ 的碳为 "S "构型；或其药学上可接受的盐或酯。还公开了肾素抑制组合物、治疗高血压的方法、制造肾素抑制化合物的方法以及用于制造肾素抑制化合物的中间体。
• Method for treating renal disease
  申请人：ABBOTT LABORATORIES

  公开号：EP0440102A1

  公开（公告）日：1991-08-07

  The present invention relates to the use of renin inhibitors and to renin inhibitor compositions for prevention, treatment, inhibition or reversal of renal dysfunction or disease, especially renal failure.

  本发明涉及肾素抑制剂和肾素抑制剂组合物在预防、治疗、抑制或逆转肾功能障碍或疾病，特别是肾衰竭方面的用途。